Menu
Search
|

Menu

Close
X

Cellular Biomedicine Group Inc CBMG.OQ (NASDAQ Stock Exchange Global Market)

19.80 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 19.80
Open --
Volume --
3m Avg Volume 18,025
Today’s High --
Today’s Low --
52 Week High 22.75
52 Week Low 8.32
Shares Outstanding (mil) 17.01
Market Capitalization (mil) 330.77
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
1
FY15
3
EPS (USD)
FY18
-0.507
FY17
-2.884
FY16
-2.063
FY15
-1.694
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
1,143.15
8.04
Price to Book (MRQ)
vs sector
4.24
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
0.00
17.43
LT Debt to Equity (MRQ)
vs sector
0.00
13.25
Return on Investment (TTM)
vs sector
-61.25
13.23
Return on Equity (TTM)
vs sector
-61.49
15.27

EXECUTIVE LEADERSHIP

Terry Belmont
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Bizuo Liu
Chief Executive Officer, Interim Chief Financial Officer, Secretary, Since 2016
Salary: $155,491.00
Bonus: --
Yihong Yao
Chief Scientific Officer, Since 2015
Salary: --
Bonus: --
Xia Meng
Head of Early Diagnosis & Intervention, Since 2018
Salary: --
Bonus: --
Richard Wang
Chief Operation Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

19925 Stevens Creek Blvd Ste 100
CUPERTINO   CA   95014-2384

Phone: +1408.9737884

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.

SPONSORED STORIES